Bactroban Cream

Bactroban is a prescription topical antibiotic cream containing mupirocin 2%, manufactured by GSK. It's used to treat bacterial skin infections caused by Staphylococcus aureus (including MRSA) and Streptococcus: primarily impetigo, infected traumatic skin lesions (cuts, abrasions, and minor wounds that have become infected), and folliculitis. Unlike Fucidin H, which combines an antibiotic with a steroid for infected eczema, Bactroban contains only an antibiotic and has no anti-inflammatory component. It's the right medicine when there's a primary bacterial skin infection or a secondarily infected wound, rather than an infected inflammatory skin disease where inflammation is also a significant feature.

The three products are related in that they're all topical antibacterials used on the skin, but they differ in mechanism, spectrum, and appropriate use. Fucidin cream (fusidic acid 2%) treats bacterial infections, mainly Staphylococcus aureus and Streptococcus, by blocking a bacterial protein synthesis step. Fucidin H adds hydrocortisone to fusidic acid, making it specifically suited for infected eczema where both infection and inflammation need treating. Bactroban (mupirocin 2%) covers a similar bacterial spectrum but works through a completely different mechanism that gives it two specific advantages: no cross-resistance with other antibiotics, and activity against MRSA where fusidic acid may fail. NICE guidelines now favour mupirocin over fusidic acid for localised impetigo, partly because of rising fusidic acid resistance and partly because mupirocin has a better evidence base for impetigo specifically. When impetigo is the diagnosis, Bactroban is generally the first-line choice. When infected eczema is the diagnosis, Fucidin H is generally the first-line choice.

Mupirocin works through a mechanism entirely unique among antibiotics. Most antibiotics target bacterial cell walls, cell membranes, or ribosomes. Mupirocin targets a specific enzyme called isoleucyl-tRNA synthetase, which bacteria need to incorporate the amino acid isoleucine into new proteins. When this enzyme is blocked, protein synthesis grinds to a halt and the bacteria can't grow or reproduce. Because no other antibiotic class targets this enzyme, bacteria that have become resistant to penicillin, cephalosporins, erythromycin, or fusidic acid are still fully susceptible to mupirocin. This is why mupirocin remains effective against MRSA strains that have become resistant to multiple other antibiotics.

Apply a small amount of the cream to the affected area three times a day. Cover only the infected patch; applying it to large areas of surrounding healthy skin is not needed and increases resistance risk. Use a cotton swab or clean fingertip rather than putting the nozzle directly onto the skin. Cover the area with a light dressing if needed, particularly for impetigo where keeping crusts moist helps the medicine penetrate. The standard course is 5 to 7 days, and courses should not extend beyond 10 days. If the skin hasn't clearly improved by day 5, go back to your GP rather than continuing without review.

The same antibiotic resistance principle that applies to topical fusidic acid applies to mupirocin, perhaps even more urgently. Mupirocin resistance develops with prolonged or repeated exposure, and high-level mupirocin resistance (mediated by a gene called mupA) renders the antibiotic completely ineffective. Preserving mupirocin's effectiveness matters particularly because of its MRSA activity; losing mupirocin to widespread resistance would remove one of the most useful tools for managing community MRSA infections. UK guidelines from NICE, the UK Health Security Agency, and the British Association of Dermatologists all specify short courses of no more than 5 to 10 days, no prophylactic use, and no rotation as maintenance therapy for chronic skin conditions. Using Bactroban beyond the prescribed duration or reaching for it for every minor skin complaint accelerates resistance without clinical benefit.

For localised, non-bullous impetigo in adults and children, mupirocin is the first-line topical treatment per NICE guidelines. Impetigo is a highly contagious superficial skin infection that produces honey-coloured crusting, typically around the mouth and nose but potentially anywhere on the body. For small, localised patches (limited in number and size), topical mupirocin applied three times daily for 5 to 7 days clears the infection in most cases. For widespread impetigo, multiple patches, bullous (blister-forming) impetigo, or impetigo in an immunocompromised patient, oral antibiotics (typically flucloxacillin or, if MRSA is suspected, a choice guided by sensitivities) are usually needed rather than topical treatment alone. During treatment, affected children should stay away from school or nursery until the lesions are crusted over and healing.

Yes, and this is one of its most clinically valuable properties. MRSA (methicillin-resistant Staphylococcus aureus) is resistant to many commonly used antibiotics, including all penicillins and most cephalosporins. Because mupirocin targets a completely different bacterial enzyme, MRSA strains are typically fully susceptible to mupirocin. Bactroban cream is used both to treat active MRSA skin infections and as part of MRSA decolonisation protocols, where it's applied to identified skin sites (such as skin fold areas, wounds, or areas of eczema) alongside the separate Bactroban nasal ointment to clear MRSA carriage before surgery or in recurrently infected patients. If you've been told you're carrying MRSA and have been given Bactroban as part of a decolonisation protocol, the instructions from your infection control team or GP take precedence over the standard short-course guidance.

There are three distinct Bactroban products and they're not interchangeable. Bactroban cream (2% mupirocin in a cream base) is for use on skin infections, particularly on traumatised, broken, or weeping skin, since the cream base doesn't contain anything harmful if absorbed through a wound. Bactroban ointment (2% mupirocin in a polyethylene glycol/PEG base) is also used on skin but should not be applied to large open wounds or extensive burns, because the PEG base can be absorbed in significant quantities through broken skin and cause kidney damage. The ointment is reserved for intact or mildly broken skin. Bactroban nasal ointment (mupirocin calcium 2%) is a completely different formulation designed specifically for application inside the nostrils as part of MRSA decolonisation, and should never be used on skin in place of the skin products.

Bactroban cream is generally very well tolerated, particularly for short courses. The most commonly reported effects are mild local burning or stinging at the application site and occasional itching. Allergic contact dermatitis to mupirocin is uncommon but has been reported, appearing as a spreading rash or increased irritation rather than the expected improvement. Headache has been reported rarely, thought to relate to minor systemic absorption. If a reaction seems to be worsening rather than settling, stopping the cream and seeking medical advice is the right approach. The ointment base of the cream formulation is well tolerated on skin in most people.

Yes. Mupirocin is widely used in children of all ages for impetigo and infected skin lesions, including in young infants where impetigo is common. The cream is applied in the same way as in adults, adjusted for the smaller area of skin being treated. For children with impetigo, keeping them away from school or nursery until lesions are crusted over and dry is an important part of limiting spread to other children. If a child's impetigo is widespread, if it's returning promptly after treatment, or if it's failing to respond to topical treatment, oral antibiotics may be needed and a GP review is the right step rather than repeating the topical course.

The safety data for mupirocin in pregnancy is limited, as with most topical antibiotics, but systemic absorption from the cream applied to small areas is very low and no specific harms have been identified in human pregnancy. Most clinicians are comfortable prescribing Bactroban for localised skin infections in pregnancy when clinically needed, applying the short-course principle. In breastfeeding, the same low systemic absorption means the medicine is generally considered compatible. As with other topical antibiotics, avoid applying to the breast or nipple area where the baby could ingest the cream directly or through skin contact during feeds. A GP or pharmacist can advise on individual circumstances.

Very few. Chloramphenicol, an antibiotic used in some eye and ear drops, directly antagonises mupirocin's action by competing for the same bacterial target. Using both simultaneously in the same area reduces the effectiveness of both, so they should not be combined. Other drug interactions are not clinically significant for topical use at standard doses. As always, mentioning Bactroban to any prescriber who is starting a new medicine is sensible, even though interactions are uncommon.

Several features call for a clinical review rather than completing the course. Spreading redness, red streaks extending from the infected area, fever, feeling systemically unwell, or swollen nearby lymph nodes while using Bactroban suggest the infection is spreading deeper into the skin (cellulitis) or towards the bloodstream, both of which need oral or intravenous antibiotics rather than topical treatment alone. An infected area that hasn't improved clearly by day 5 of treatment should be reviewed: the bacteria may be resistant to mupirocin, the diagnosis may need revisiting, or a swab for culture and sensitivities may be needed to guide the right treatment. Bullous (blister-forming) impetigo, impetigo in an immunocompromised patient, or impetigo covering a large or spreading area all generally need oral antibiotics rather than topical treatment. For recurrent skin infections, particularly those involving MRSA, a GP or specialist review can set up a proper decolonisation plan rather than repeated short courses of topical antibiotics, which accelerates resistance without addressing the underlying carriage.